Aug 4, 2026 06:30AM
Jul 21, 2026 10:00AM
Jul 21, 2026 10:00AM
Jul 21, 2026 10:00AM
Jul 21, 2026 10:00AM
Jul 17, 2026 07:07AM
Jul 16, 2026 06:45AM FDA approves Merck's Lipfendra as first oral PCSK9 inhibitor
Jul 16, 2026 06:45AM
Jul 15, 2026 07:00AM
Jul 15, 2026 07:00AM
Jul 15, 2026 06:45AM
Jul 15, 2026 06:45AM
Jul 10, 2026 02:10PM
Jul 10, 2026 02:10PM FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With Padcev® (enfortumab vedotin-ejfv), as Treatment Before and After Surgery for Ad
Jul 8, 2026 08:00AM
Jul 8, 2026 08:00AM
Jun 29, 2026 06:45AM
Jun 29, 2026 06:45AM
Jun 25, 2026 06:45AM
Jun 25, 2026 06:45AM
Jun 24, 2026 08:30AM Next-Generation DNA Repair Inhibitors Could Capture Billions in Emerging Market
Jun 24, 2026 08:30AM
Jun 24, 2026 06:45AM
Jun 24, 2026 06:45AM
Jun 18, 2026 06:45AM
Jun 18, 2026 06:45AM
Jun 12, 2026 04:10PM
Jun 12, 2026 04:10PM FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Ce
Jun 8, 2026 04:35PM
Jun 8, 2026 04:35PM
Jun 8, 2026 04:30PM
Jun 8, 2026 04:30PM
Jun 3, 2026 09:00AM
May 29, 2026 06:49AM
May 29, 2026 06:45AM FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
May 22, 2026 07:55AM
May 22, 2026 07:55AM
May 13, 2026 08:30AM
May 12, 2026 06:45AM
May 12, 2026 06:45AM
May 7, 2026 08:00AM
May 5, 2026 08:45AM Merck completes $5.8 billion acquisition of Terns Pharmaceuticals
May 5, 2026 08:45AM
Apr 30, 2026 06:30AM
Apr 21, 2026 02:11PM
Apr 21, 2026 02:11PM
Apr 21, 2026 08:37AM
Apr 21, 2026 06:45AM
Apr 21, 2026 06:45AM Merck and Eisai Provide Update on Phase 3 LITESPARK-012 Trial Evaluating First-Line Combination Treatments for Certain Patients With Advanced Renal Cell Carcinoma (RCC)
Apr 20, 2026 09:51AM

327,397 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All